Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium

Elisa V. Bandera & P. M. Webb et al. · 2024-07-18

Abstract

Background

Tea and coffee are the most frequently consumed beverages in the world. Green tea in particular contains compounds with potential anti-cancer effects, but its association with survival after ovarian cancer is uncertain.

Methods

We investigated the associations between tea and coffee consumption before diagnosis and survival using data from 10 studies in the Ovarian Cancer Association Consortium. Data on tea (green, black, herbal), coffee and caffeine intake were available for up to 5724 women. We used Cox proportional hazards regression to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI).

Results

Compared with women who did not drink any green tea, consumption of one or more cups/day was associated with better overall survival (aHR = 0.84, 95% CI 0.71–1.00, p-trend = 0.04). A similar association was seen for ovarian cancer-specific survival in five studies with this information (aHR = 0.81, 0.66–0.99, p-trend = 0.045). There was no consistent variation between subgroups defined by clinical or lifestyle characteristics and adjustment for other aspects of lifestyle did not appreciably alter the estimates. We found no evidence of an association between coffee, black or herbal tea, or caffeine intake and survival.

Conclusion

The observed association with green tea consumption before diagnosis raises the possibility that consumption after diagnosis might improve patient outcomes.

Funding
SURVEILLANCE EPIDEMIOLOGY & END RESULTS PROGRAMCancer Center AdministrationObesity in ovarian cancer prognosisU.S. Department of Health & Human Services | National Institutes of Health (NIH) Grant R01-CA112523, R01-CA87538Department of Health | National Health and Medical Research Council (NHMRC) Grant 209057, 396414, 1074383Dana-Farber/Harvard Cancer Center Ovarian Cancer SPOREU.S. Department of Defense (United States Department of Defense) Grant W81XWH-10-1-02802PathologyUnited States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (CDMRP) Grant W81XSH-16-2-0010U.S. Department of Health & Human Services | National Institutes of Health (NIH) Grant NIH-K07-CA095666, R01-CA83918, NIH-K22-CA138563, P30-CA072720Genes, Hormones & Environment in an Ovarian Cancer ModelU.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) Grant Intramural Research ProgramU.S. Department of Health & Human Services | National Institutes of Health (NIH) Grant R01-CA58598, N01-CN-55424, N01-PC-67001U.S. Department of Health & Human Services | National Institutes of Health (NIH) Grant P01-CA17054, P30-CA14089, R01-CA61132, N01-PC67010, R03-CA113148, R03-CA115195, N01-CN025403Phytoestrogens, alcohol, and endometrial cancer riskSteroid Hormone Genes and Ovarian Cancer RiskEpidemiology of Ovarian Cancer:New HypothesesRutgers Cancer Institute of New Jersey (Cancer Institute of New Jersey) FundingU.S. Department of Health & Human Services | National Institutes of Health (NIH) Grant R01-CA61107The Progesterone Receptor Gene and Ovarian Cancer RiskCollaborative Genetic Study of Ovarian Cancer RiskCancer Research Training and Education CoordinationESTROGEN, DIET, GENETICS AND ENDOMETRIAL CANCEROvarian Cancer and Gonadotropin SignalingU.S. Department of Health & Human Services | National Institutes of Health (NIH) Grant R01-CA54419, P50-CA105009Hormone Therapy and Risk of Ovarian CancerSURVEILLANCE EPIDEMIOLOGY AND END RESULTSRutgers Cancer Institute of New Jersey Grant -U.S. Department of Health & Human Services | National Institutes of Health FundingCancer Council Victoria FundingVicHealth FundingKræftens Bekæmpelse FundingMermaid I and Mermaid III FundingCalifornia Cancer Research Program FundingOvarian Cancer Research Fund Funding

NCI NIH HHS

N01 PC067010

NCI NIH HHS

P30 CA072720

NCI NIH HHS

K22 CA138563

NCI NIH HHS

P50 CA105009

NCI NIH HHS

P30 CA008748

NCI NIH HHS

R01 CA054419

NCI NIH HHS

K07 CA095666

NCI NIH HHS

R01 CA112523

NCI NIH HHS

R01 CA087538

NCI NIH HHS

R03 CA113148

NCI NIH HHS

R01 CA058598

NCI NIH HHS

P30 CA014089

NCI NIH HHS

R01 CA083918

NCI NIH HHS

R03 CA115195

NCI NIH HHS

P01 CA017054

NCI NIH HHS

N01 CN025403